Objective
• Germany did not issue any negative recommendations for any of the 20 Orphan Drug assessments -However, 7 assessments (35%) where the additional benefit was not quantifiable would have been negative if the products did not have an EMA Orphan Drug designation and a legislated «implicit additional clinical benefit» -Potential changes to the German drug assessment mechanism could impact this on definition and resulting evaluations
• Germany and France base their HTAs primarily on additional clinical value criteria, comparing the drug to existing treatment options, if any exist, or standard of care. As a consequence, there is substantial convergence in assessments, with only three cases having highly divergent assessments
• In England, Scotland and Canada, pharmacoeconomic criteria such as cost-effectiveness and cost-utility have a greater weight in the assessments -Stringent application of pharmacoeconomic criteria, such as cost-effectiveness and cost-utility, is associated with a significantly lower number of positive recommendations, especially in England (0%), Scotland (35%) and Canada (8%)
-When comparing evaluation of Oncology Orphans in England and Scotland, there are significant discrepancies between the recommendations issued by the NICE and the SMC, with the latter issuing a higher number of positive recommendations, primarily as the result of greater importance attributed to the opinion of patients and clinicians (PACE groups)
• Providing evidence of low budget impact (Netherlands) and negotiating a price reduction or a Patient Access Scheme (Scotland, Canada) increases probability of positive or partially positive recommendation
Conclusions
• Analyzed all orphan drug assessments conducted by the G-BA between Jan 2011 and May 2015. Compared them with other HTA assessments from the EU (France, England, Netherlands, Scotland) and Canada. Data collection cut off was May 31, 2015
• 20 assessments for 19 Orphan Drugs were completed by the G-BA by end of May 2015 and were comparable with assessment of at least one other HTA agency -Ivacaftor was assessed twice by the G-BA, the first assessment being for the G551D mutation while the second one was for other 8 mutations
• Orphan Drug assessments were divided in three subgroups:
-Ultra-orphan Drugs, i.e. drugs with both orphan drug designation(s) and approved indication(s) for conditions with prevalence of < 1:50,000 (as per NICE definition; 5 assessments); -Oncology Orphan Drugs i.e., all orphan drugs with both orphan drug designation(s) and approved indication(s) in oncology (9 assessments); -Other Orphan Drugs, i.e. orphan drugs not included in the previous two groups (6 assessments)
• All products and related assessments by the G-BA and other HTA agencies were also grouped in three categories -positive, partially positive and negative (Table 1) -to verify potential commonalities and/or differences in benefit evaluations and therefore in reimbursement and drug access 
Methods
• German G-BA and French HAS are the only agencies that reviewed all Orphan Drugs
• Other four HTA agencies completed between 14 and 5 evaluations, with these differences seemingly due to local criteria for reviews and / or launch timing; e.g.: NICE has not regularly reviewed ultra-orphan drugs; ZIN evaluates only outpatient drugs, therefore hospital oncology orphans are by definition not assessed 
